UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A randomized trial of social media from Circulation

Circulation (New York, N.Y.), 2015-01, Vol.131 (1), p.28-33

2015

Volltextzugriff (PDF)

Response to letters regarding article, "A randomized trial of social media from Circulation"

Circulation (New York, N.Y.), 2015-03, Vol.131 (13), p.e396-e396

2015

Volltextzugriff (PDF)

Pharmacological Treatment and Current Management of Peripheral Artery Disease

Circulation research, 2015-04, Vol.116 (9), p.1579-1598

2015

Volltextzugriff (PDF)

Not Everything That Glitters is Gold, Even When Randomised

European journal of vascular and endovascular surgery, 2023-09, Vol.66 (3), p.369-370

2023

Volltextzugriff (PDF)

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Circulation (New York, N.Y.), 2019-05, Vol.139 (22), p.2528-2536

2019

Volltextzugriff (PDF)

Contemporary Medical Management of Peripheral Artery Disease

Circulation research, 2021-06, Vol.128 (12), p.1868-1884

2021

Volltextzugriff (PDF)

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Circulation (New York, N.Y.), 2018-01, Vol.137 (4), p.338-350

2018

Volltextzugriff (PDF)

Microvascular Disease, Peripheral Artery Disease, and Amputation

Circulation (New York, N.Y.), 2019-08, Vol.140 (6), p.449-458

2019

Volltextzugriff (PDF)

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials

Circulation (New York, N.Y.), 2019-04, Vol.139 (17), p.2022-2031

2019

Volltextzugriff (PDF)

Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials

Thrombosis and haemostasis, 2024-07, Vol.124 (7), p.649-655

2024

Volltextzugriff (PDF)

Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology

Circulation (New York, N.Y.), 2019-07, Vol.140 (1), p.80-91

2019

Volltextzugriff (PDF)

Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial

Circulation (New York, N.Y.), 2023-06, Vol.147 (25), p.1891-1901

2023

Volltextzugriff (PDF)

Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial

Circulation (New York, N.Y.), 2020-04, Vol.141 (15), p.1227-1234

2020

Volltextzugriff (PDF)

Stepping Into the Future of Care for Patients With Peripheral Artery Disease

Circulation (New York, N.Y.), 2024-06, Vol.149 (24), p.1862-1864

2024

Volltextzugriff (PDF)

Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis–Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50)

Circulation (New York, N.Y.), 2016-03, Vol.133 (10), p.997-1005

2016

Volltextzugriff (PDF)

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction: Subanalysis From the DECLARE-TIMI 58 Trial

Circulation (New York, N.Y.), 2019-05, Vol.139 (22), p.2516-2527

2019

Volltextzugriff (PDF)

Polyvascular disease and risk: When two is not better than one

Vascular medicine (London, England), 2018-12, Vol.23 (6), p.531-533

Bonaca, Marc P

2018

Volltextzugriff (PDF)

New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?

Atherosclerosis, 2021-02, Vol.319, p.51-61

2021

Volltextzugriff (PDF)

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial

Circulation (New York, N.Y.), 2015-03, Vol.131 (12), p.1047-1053

2015

Volltextzugriff (PDF)

Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety

Circulation (New York, N.Y.), 2020-12, Vol.142 (23), p.2219-2230

2020

Volltextzugriff (PDF)

Vorapaxar in Patients With Peripheral Artery Disease: Results From TRA2°P-TIMI 50

Circulation (New York, N.Y.), 2013-04, Vol.127 (14), p.1522-1529

2013

Volltextzugriff (PDF)

Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction

Circulation (New York, N.Y.), 2016-07, Vol.134 (4), p.304-313

2016

Volltextzugriff (PDF)

Recapturing the Team Approach to Vascular Care

Annals of vascular surgery, 2024-04, Vol.101, p.84-89

2024

Volltextzugriff (PDF)

Sex differences in guideline-directed medical therapy in 2021–22 among patients with peripheral artery disease

Vascular medicine (London, England), 2023-06, Vol.28 (3), p.233-235

2023

Volltextzugriff (PDF)

Society for Vascular Surgery appropriate use criteria for management of intermittent claudication

Journal of vascular surgery, 2022-07, Vol.76 (1), p.3-22.e1

2022

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Aktive Filter

ThemaPeripheral Vascular Disease

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(62)

Publikationsform

Artikel
(73)
Buchkapitel
(1)

Sprache

Englisch
(74)

Erscheinungsjahr

n.n

Thema

Cardiovascular System & Cardiology
(74)
Life Sciences & Biomedicine
(74)
Science & Technology
(74)
Humans
(53)
Cardiac & Cardiovascular Systems
(48)
Female
(34)
Male
(34)
Aged
(29)
Middle Aged
(28)
Treatment Outcome
(24)
Risk Factors
(20)
Hematology
(16)
Peripheral Artery Disease
(14)
Peripheral Arterial Disease - Drug Therapy
(12)
Platelet Aggregation Inhibitors - Therapeutic Use
(11)
Double-Blind Method
(9)
Hemorrhage - Chemically Induced
(9)
Peripheral Arterial Disease - Surgery
(9)
Time Factors
(9)

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A randomized trial of social media from Circulation

Response to letters regarding article, "A randomized trial of social media from Circulation"

Pharmacological Treatment and Current Management of Peripheral Artery Disease

Not Everything That Glitters is Gold, Even When Randomised

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Contemporary Medical Management of Peripheral Artery Disease

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Microvascular Disease, Peripheral Artery Disease, and Amputation

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials

Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials

Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology

Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial

Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial

Stepping Into the Future of Care for Patients With Peripheral Artery Disease

Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis–Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50)

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction: Subanalysis From the DECLARE-TIMI 58 Trial

Polyvascular disease and risk: When two is not better than one

New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial

Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety

Vorapaxar in Patients With Peripheral Artery Disease: Results From TRA2°P-TIMI 50

Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction

Recapturing the Team Approach to Vascular Care

Sex differences in guideline-directed medical therapy in 2021–22 among patients with peripheral artery disease

Society for Vascular Surgery appropriate use criteria for management of intermittent claudication

Aktive Filter

Suchergebnisse filtern